Ongoing trials of immune checkpoint blockade in acute myeloid leukemia

Data were compiled from ( 7/2016.

TypeTherapyPrimary Identifier
Phase 1IpilimumabAcute GVHD graft rejection Autoimmune reactionSolid tumors, lymphoma and leukemia, including relapsed/refractory AML after allo-SCTNCT00060372
Phase 1IpilimumabToxicity and immunologic responseRelapsed/refractory AML or CMML or high-risk MDSNCT01757639
Phase 1/1bIpilimumab or nivolumabToxicity and MTDRelapsed leukemia, including AML, lymphoma and MM after allo-SCTNCT01822509
Phase 2Pidilizumab + DC vaccineToxicityAML in CR before cell collection for DC generationNCT01096602
Phase 2Azacytidine + nivolumabResponse rate, overall survivalRelapsed AML and frontline elderly (>65 years) AMLNCT02397720
Phase 2Idarubicin and cytarabine + nivolumabEvent-free survivalInduction in newly diagnosed AML <60 yearsNCT02464657
Phase 2NivolumabRecurrence-Free SurvivalAML in remissionNCT02532231
  • allo-SCT, allogeneic stem cell transplantation; AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; CR, complete response; DC, dendritic cell; GVHD, graft versus host disease; MDS, myelodysplastic syndrome; MM, multiple myeloma.